ArticleCell2018
Multi-regional Sequencing Elucidates the Evolution of Clear Cell Renal Cell Carcinoma.
Article in Cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Article
- The Prognostic Role of Interferon Gamma-inducible Protein 30 in Clear Cell Renal Cell Carcinoma with Immune Infiltrates.Recent patents on anti-cancer drug discovery · 2026Article
- VHL Gene Restoration Supports RCC Reprogramming to iPSCs but Does Not Ensure Line Stability.Cancers · 2025Article
- SPOCD1 expression in clear cell renal cell carcinoma: its implications for the prognosis and immunotherapy.World journal of surgical oncology · 2025Article
- Next-generation sequencing identifies the mutational signature of double primary and metastatic malignancies: A case report.Current urology · 2025Article
- Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma.Genome medicine · 2023Article
- RUNX2 interacts with SCD1 and activates Wnt/β-catenin signaling pathway to promote the progression of clear cell renal cell carcinoma.Cancer medicine · 2023Article
- Incremental value of radiomics with machine learning to the existing prognostic models for predicting outcome in renal cell carcinoma.Frontiers in oncology · 2023Article
- Article
- Heterogeneity of the tumor immune microenvironment and its clinical relevance.Experimental hematology & oncology · 2022Review
- Sensitivity ofProceedings of the National Academy of Sciences of the United States of America · 2022Article
- TGF‑β1 affects the renal cancer miRNome and regulates tumor cells proliferation.International journal of molecular medicine · 2022Article
- FECH Expression Correlates with the Prognosis and Tumor Immune Microenvironment in Clear Cell Renal Cell Carcinoma.Journal of oncology · 2022Article
- Prognostic significance of CKAP2L expression in patients with clear cell renal cell carcinoma.Frontiers in genetics · 2022Article
- Cuproptosis-related geneFrontiers in immunology · 2022Article
- Characterization of Genetic Heterogeneity in Recurrent Metastases of Renal Cell Carcinoma.Cancers · 2021Article
- Determinants of renal cell carcinoma invasion and metastatic competence.Nature communications · 2021Observational
- Significance of CD8Aging · 2021Article
- Hyperfluorescence Imaging of Kidney Cancer Enabled by Renal Secretion Pathway Dependent Efflux Transport.Angewandte Chemie (International ed. in English) · 2021Article
- USP22 promotes proliferation in renal cell carcinoma by stabilizing survivin.Oncology letters · 2020Article
Corrections and comments
- Comment on
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
Abstract
Extensive multi-regional whole-genome and -exome sequencing performed in tumors from patients with localized, as well as metastatic, clear cell renal cell carcinoma provides a comprehensive description of the tumor origin, intratumoral heterogeneity, evolution, and route to metastasis, laying the foundation for the development of precision clinical management.
Indexed as
Identifiers
29677504What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.